[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NGM Biopharmaceuticals, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100595482","phase-2-an-evaluation-of-ngm120-in-a-randomized-double-blind-placebo-controlled-study-in-participants-with-colorectal-cancer-who-have-cancer-cachexia-100595482",false,"NCT07033026","An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia","Inclusion Criteria:\n\n1. Documented active diagnosis of colorectal cancer.\n2. Cachexia defined by Fearon criteria of weight loss.\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Current active reversible causes of decreased food intake.\n2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.\n3. Have cachexia caused by other reasons.","ALL","18 Years",{"count":19,"type":20},136,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.",[26,27,28],"Colorectal Cancer","CRC (Colorectal Cancer)","Cancer Cachexia",[28,26,30],"CRC","RECRUITING","2026-03-30",{"date":34,"type":35},"2026-04-01","ACTUAL",{"date":37,"type":35},"2025-06-25",{"date":39,"type":20},"2027-12",{"name":41,"class":42},"NGM Biopharmaceuticals, Inc","INDUSTRY",28,""]